Navigation Links
Schering-Plough Reports Financial Results for 2009 First Quarter
Date:4/21/2009

non-joint venture territories such as Japan and Latin America, declined 21 percent in the first quarter of 2009 to $973 million, reflecting a 17 percent operational decrease and a 4 percent unfavorable impact from foreign exchange. Sales declined 30 percent in the U.S. In international markets, sales declined 2 percent, reflecting operational growth of 11 percent and a 13 percent unfavorable impact from foreign exchange. ZETIA in Japan, sold under a co-marketing agreement with Bayer, contributed $30 million to cholesterol franchise sales in the 2009 period.

Sales of Prescription Pharmaceuticals for the 2009 first quarter decreased 5 percent to $3.4 billion, reflecting operational growth of 5 percent and an unfavorable impact from foreign exchange of 10 percent.

Sales of REMICADE increased 2 percent (22 percent operational growth offset by 20 percent unfavorable foreign exchange impact) to $518 million in the first quarter of 2009 due to continued market growth and expanded penetration in certain indications. REMICADE, a treatment for inflammatory diseases, is marketed by Schering-Plough in countries outside the U.S. (except in Japan and certain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, pediatric Crohn's disease and ulcerative colitis.

Global sales of NASONEX, an inhaled nasal corticosteroid for allergies, totaled $306 million in the 2009 first quarter (8 percent operational growth offset by 8 percent unfavorable foreign exchange impact) as compared to $307 million in the first quarter of 2008. Strong international sales were offset by lower sales in the U.S. compared to the 2008 period.

Sales of TEMODAR, a treatment for certain types of brain tumors, increased 5 percent (16 percent operational growth offset by 11 percent unfavorable foreign exchange impact) to $247 million, with
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year
2. Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M.
3. Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
4. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
5. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
6. Schering-Plough Selects Benefit Advocates for Health Advocacy
7. Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings
8. Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
9. Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
10. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
11. Schering-Plough to Webcast R&D Update Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... was told she had an aneurysm, she figured an invasive ... "I was devastated," said Wakulich, who is 56 years old ... a serious diagnosis. Then I met Dr. Bernard Bendok who ... invasive procedure. It was something I didn,t even know was ... U.S. clinical trial to evaluate the safety and effectiveness of ...
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
(Date:7/9/2014)... Researchers from Montefiore Medical Center and the ... University will present new findings at the Alzheimer,s Association ... 17 in Copenhagen, Denmark. Data from the four abstracts ... cognitive normality to mild cognitive impairment and dementia. The ... , established in 1980 to examine healthy brain aging ...
(Date:7/9/2014)... and Infectious Diseases (NIAID), part of the National ... trial of CRS3123, an investigational oral antibiotic intended ... difficile ) infection. CRS3123 (previously known as REP3123) ... growth while sparing normal intestinal bacteria. , The ... healthy men and women ages 18 to 45 ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... help healthier people, but others worry about risks , ... Food and Drug Administration in February approved the use ... with normal cholesterol levels, cardiologist Dr. Steven ... go with the scientific evidence," said Nissen, who is ...
... ... facing executives and HR practitioners in a changing workplace at the 25th Meeting of ... ... deliver four noteworthy presentations at the 2010 Society for Industrial & Organizational Psychology Meeting ...
... ... Flow for Health Care Providers, Medical Facilities & Hospital’s, Reduces Patient Receivables, Reduces Patient-Pay ... Associated with Patient Billing and Collections , ... (PRWEB) April 2, 2010 -- Medical Pay Solutions, a national ...
... ... Legend is Officially Released and Now Available For Sale , ... New York, N.Y. (PRWEB) April 2, 2010 -- New ... Education of a Tennis Player,” is officially released today and is now available in book ...
... Value in Health , the study assessed the current ... fairness. The researchers concluded that extending the hotly-debated ... in terms of both economic efficiency and equity. The ... with similar age distributions. "Screening only older ...
... Memorial Health Care is undertaking an electronic medical record ... the project is a multi-year, multi-entity corporate initiative to ... reduce variability in processes and workflows across the system. ... over the next four years, the way UMass Memorial ...
Cached Medicine News:Health News:Should Cholesterol Drugs Be Used By Those Without High Cholesterol? 2Health News:Should Cholesterol Drugs Be Used By Those Without High Cholesterol? 3Health News:Atlanta Group Presents Issues in Business Psychology at National Conference 2Health News:Atlanta Group Presents Issues in Business Psychology at National Conference 3Health News:Atlanta Group Presents Issues in Business Psychology at National Conference 4Health News:Medical Pay Solutions Introduces the Revenue Maximizer to the Healthcare Industry; The Solution to 'Ever Increasing Direct To Patient Pay Issues' 2Health News:Medical Pay Solutions Introduces the Revenue Maximizer to the Healthcare Industry; The Solution to 'Ever Increasing Direct To Patient Pay Issues' 3Health News:Medical Pay Solutions Introduces the Revenue Maximizer to the Healthcare Industry; The Solution to 'Ever Increasing Direct To Patient Pay Issues' 4Health News:Medical Pay Solutions Introduces the Revenue Maximizer to the Healthcare Industry; The Solution to 'Ever Increasing Direct To Patient Pay Issues' 5Health News:Rod Laver Memoir 'The Education Of A Tennis Player' Officially Released By New Chapter Press 2Health News:Rod Laver Memoir 'The Education Of A Tennis Player' Officially Released By New Chapter Press 3Health News:UMass Memorial health care develops fully integrated EMR 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
(Date:1/14/2014)... Critical Care, a LifeCentre partner practice, located at 165 Fort Evans ... in Loudoun County to receive a small ... Barnes , Medical Director, is a well-seasoned veterinarian of more than ... are avid scuba divers. "As altitude skiers and hikers, we recognize ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... SUPERIOR, Colo., Jan. 10, 2011 Key Equipment ... finance companies and an affiliate of KeyCorp (NYSE: ... entered into an exclusive, long term, program agreement with ... America is the U.S. distributor of Hitachi Medical Corporation,s ...
... Jan. 8, 2011 - Bayer HealthCare Pharmaceuticals has become aware ... pads, swabs and swabsticks manufactured by the Triad Group and ... safety, Bayer wants to ensure that U.S. patients and physicians ... The recall of the Triad Group alcohol ...
Cached Medicine Technology:Key Equipment Finance Enters Long-Term Program Agreement With Hitachi Medical Systems America 2Key Equipment Finance Enters Long-Term Program Agreement With Hitachi Medical Systems America 3Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 2Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: